Mouse Anti-Mouse mAbs

Benefits of mouse anti-mouse mAbs
Benefits of mouse anti-mouse mAbs

Recombinant monoclonal antibodies for in vivo use

InvivoGen offers an expanding collection of InvivoFit™ recombinant mouse or murinized anti-mouse monoclonal antibodies (mAbs) that were engineered to limit their immunogenicity upon repeated injections in mice.

Our collection includes mAbs targeting:
  - Immune checkpoints: mCTLA-4, mPD-1, mPD-L1, and mTIGIT
  - Lymphocyte markers: mCD20mCD3, mCD4, and mCD8
  - Tumor-associated antigens: gp75
  - E. coli β-galactosidase for isotype controls
These mAbs are produced in Chinese hamster ovary (CHO) cells and are provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo studies.


Key Features:

  • Sequence is 65% to 100% murine
  • Guaranteed sterile, endotoxin level: <1 EU/mg
  • Suitable for parenteral delivery in mice (azide-free)
  • Low aggregation: < 5%
  • Produced in animal-free facilities and defined media


InvivoGen's recombinant mouse and murinized anti-mouse mAbs include antibodies for which the sequence is either 100% mouse origin (constant and variable regions), or ~65% mouse origin (constant regions), respectively. The minimal use of xenogeneic sequences limits the immunogenicity of the mAb [1]. Indeed, a major pitfall encountered in murine in vivo studies aimed at evaluating the activity of a mAb upon repeated injections is the decrease and loss of antibody performance if its sequence is not of mouse origin. Repeated injections in mice lead to anti-species antibody generation by the host (e.g. anti-rat antibodies if the mAb was produced in rats). This occurrence increases as the fraction of non-mouse sequences increases. Replacing xenogeneic sequences with mouse sequences reduces antibodies' immunogenicity, and thus helps retain their activity in vivo.

Learn more on SARS-CoV-2Learn more about the importance of mAb murinization for in vivo mouse models.

InvivoGen provides murine IgG1e3 and murine IgG2a isotype control mAbs for use with the mouse anti-mouse mAbs. These antibodies comprise the variable region of a mouse monoclonal antibody targeting E. coli β-galactosidase and the constant region of corresponding isotypes.



1. Brüggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157.

Customer Service
& Technical Support
Contact us
Shopping cart is empty